Ebo­la tri­al stopped ear­ly as Re­gen­eron, Ridge­back ther­a­pies cut death risk; Mer­ck inks deal to test Keytru­da with On­colo­gie's an­ti­body

→ As armed rebels con­flict with con­tain­ment ef­forts to thwart the dead­ly Ebo­la virus in the Con­go, a tri­al test­ing the vi­a­bil­i­ty of four ex­per­i­men­tal ther­a­pies (from Mapp­Bio/ZMapp, Gilead $GILD/remde­sivir, Re­gen­eron $REGB/REGN-EB3, and Ridge­back Bio­ther­a­peu­tics/mAb114) in the re­gion has been stopped ear­ly, be­cause pa­tients giv­en REGN-EB3 or mAb114 were found to have a high­er chance of sur­vival ver­sus the oth­er two ther­a­pies, af­ter in­ter­im mor­tal­i­ty da­ta from 499 pa­tients was re­viewed, the NIH said on Mon­day. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER